Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It doesn’t look like $.05’s will be available for much longer.
The daily chart is looking great also.
The 12-day line is above the 26-day line on the MACD indicator, and both are about to cross over the centerline.
The last time this happened, it ran from $.05 to $.10
Now is the time to buy.
No, CDB Unlimited (EDXC) does not serve the pet-CBD market exclusively. They do have a few other products, including a beverage line, oils, and topicals. As far as I understand, CBD Unlimited only provides the CBD for these products.
I think the point of differentiation with Canbiola remains, however, in that they carry the usual retail products, along with their medical device product. They serve the retail community, along with the medical community, and soon the active-duty military and veteran community.
Many of these CBD companies carry the usual retail products - some more than others - but when you can add unique revenue streams to your business model, it creates a huge advantage over competitors.
Don’t get me wrong, CBD Unlimited is doing incredibly well right now, I just think Canbiola will do better.
Agreed. I think that would-be longs, and people that would otherwise be buyers, get mixed signals when filings are submitted late.
The upside in the case, however, is that 10Q’s are only given a 5-business day extension, instead of the 15-business day extension for 10K’s.
Worst case, Canbiola submits an extension on May 16, gets 5 business days, and then has until May 23.
When you look back at past 10K filings, they have been released within days of the deadline. What stands out to me about this year’s 10K, is that it was released unusually late. They literally waited until the last hour to release it.
We all knew that 2018 revenue would be several times over 2017 revenue, but we also know that 2019 Q1 revenue will be our first look into CANB’s SAM revenue - the real power behind Canbiola’s potential.
For investors (and even traders), the 2018 10K was pretty highly anticipated, and I think the recent trading volume confirms that interest. In comparison, however, the 2019 Q1 10Q is EXTREMELY anticipated because everyone knows that 2019 Q1 is the first quarter with all of the wheels turning and working together.
My theory is this:
Canbiola likely held onto the 10K for so long so that they could release it as close as possible to the 2019 Q1 10Q, for maximum effect.
As a result, I expect to see the momentum from the 10K build a solid springboard for us moving into May. Assuming the 10Q is released without delay, it will be the single most important catalyst for CANB this year - likely resulting in new highs.
Another element to consider as we move into May, is that we’ve now seen our second CVSI-like run in the CBD sector (as far as I’m aware). Most recall CV Sciences’ run from $.40 to nearly $3.00. If not, they certainly remember last year’s run up to $9.00.
In similar fashion, we just watched
CBD Unlimited ($EDXC) run from $.04 to $.75 in the last few weeks. What’s more, their run doesn’t seem to be slowing down, and they look well positioned to exceed CVSI’s gains last year.
When several companies boast these sorts of gains, all it does is draw more attention to the sector. At this point, it seems clear that we are moving into heavy mania territory. Investors and traders alike are looking for the next CVSI, the next EDXC - the next 2,000% gainer.
People who missed the CVSI opportunity, along with those that missed the EDXC opportunity, aren’t going to let the next undervalued company pass them by. To that end, Canbiola is one of the most undervalued CBD companies that brings in serious revenue.
Altogether, I think the momentum we build from the 2018 10K, along with the anticipation we see for the 2019 Q1 10Q, and manic buying we’re seeing in other CBD companies, is going to set Canbiola up to be one of the few 2,000+ gainers this year.
The last 10Q was followed by a succession of PR’s - I’m expecting the same service over the next few days, and even into next week.
The leg prior to that ran up to $.18 before giving back about 30% and finding support around $.125.
20-30% pull backs have followed each leg up since January.
The last leg ran to $.40 and gave back 25% over the following 2 weeks. After hitting $.75, a 25% pull back puts us in the high $.50’s.
However, with the way this thing has been performing, I wouldn’t be surprised if it held $.65 and started the next leg up from here.
It’s that dang A/S count, I tell you!
I didn’t expect $.05’s until later this week or early next week.
This thing is really moving - hold on everyone!
2019 Q1 is less than a month away, I’m expecting new highs by then.
Looks like you just get what you asked for!
Incredible run today!
It looks like the trend is reversing. I expect consolidation to bring us down to $.55 or so, might be a good entry point for the next leg - which will likely take us over $1.00.
Congrats to all the longs whom will be retiring soon!
This is only day #1 after 2018 financials were released and we’re up nearly 20% on heavy volume.
If that’s the case, I can’t wait to see how the market reacts to 2019 Q1 financials in a couple weeks!
SAM revenue is going to blow the top off of this thing.
Typical trading action after traders flood in.
The 10K news attracted a lot of traders this morning, most of them sold for 15-20% gain this morning.
As traders move on to other tickers, we will continue to climb over the next few weeks.
All true.
The revenue story is only going to get better in 2019.
Just like $EDXC expects to generate $24 million from retail sales in 2019, Canbiola is expecting to generate $24 million from their SAM units alone.
The best part is that SAM units are only one source of revenue for $CANB.
Yes, I have been following $EDXC for a few months now.
Just like Canbiola, CBD Unlimited traded between the $.04 - .05 range for quite some time. Yet, almost immediately upon releasing 2018 financials, the company soared.
The most exiting thing for CBD Unlimited, is that their momentum hasn’t shown any sign of slowing down. They’ve had almost no major pull backs, and they look prepared to breach $1.00 soon.
For Canbiola, as a comparable company, with similar revenue and similar projected growth, I think that bodes well.
For the sector as a whole, I think it’s even better.
Consider this:
CBD Unlimited is doing a lot of things right, but they also:
1) ran into the red last year with a net loss,
2) serve a very niche, almost obscure market (CBD for pets),
3) carry limited SKU’s, and
4) derive nearly all revenue from one source: retail.
The fact that a company like that can garner enough attention to drive their stock up more than 1500% in 3 months shows just how explosive this sector is.
The $EDXC story tells us that people are looking for CBD plays, and the FOMO is palpable.
Agreed, the next few days will be very critical to Canbiola’s success.
The numbers were actually pretty good - better than expected - but the onus will be on Canbiola executives to capitalize on the data.
Over the next couple of weeks, I’d like to see Canbiola spreading the word about their performance and providing confidence to would-be investors. The information is useless if nobody knows about it.
That means reiterating their excellent YoY/QoQ growth, providing guidance on 2019 revenue, and updating the market on each of their revenue streams.
Canbiola has nothing but potential from here - it all just comes down to execution.
Yes, another HUGE point to consider: this report does not include Canbiola’s blockbuster SAM deal.
I am wondering if the increased Cost of Products in Q4 is due in part to rolling out the SAM devices - getting units delivered to practitioners.
With that in mind, CBD Unlimited ($EDXC) is generating similar revenue but boasting a Market Cap that is 12X’s more valuable.
At 12X, CANB should be trading much closer to $.50/share.
For comparative purposes, another CBD company (CBD Unlimited) reported nearly the same year-end numbers and is currently trading at a $160 million + Market Cap.
Just like Canbiola’s SAM revenue projections for 2019 ($24 million), CBD Unlimited is expecting for their retail revenue to generate $2 million per month in 2019 (or $24 million).
As I see it, CANB is severely undervalued with a $14 million Market Cap.
It also appears that Total Revenue for 2018 exceeded many of the projections provided by others on this board - always a good thing!
I’m not a financial expert, but some of the biggest take-aways from the 10-K seem to be:
1) Cost of Product sales was $405,000; Product Revenue was $651,000 - which means that Canbiola is making around 60% profit margin on its product.
2) Total Revenue for 2017 was $122,000; Total Revenue for 2018 was $668,000 - which means Canbiola is demonstrating 450% YoY growth.
From here, things look pretty good. I will be looking forward to more detailed analyses from other posters.
I noticed that also, but I wouldn’t read much into it.
SEC permits an executive officer of the registrant to sign and submit the Form 12b-25.
Worst case, it was a clerical mistake.
Using the processing time estimate provided by the source below (approximately 10 pages per hour), and the length of last year’s 10-K, it appears that the processing time could be several business days.
https://www.newsfilecorp.com/filing/edgar/faqs.php#14
According to this source, “EDGARizing” a filed document is very labor intensive.
I suspect the company likely made the deadline, but processing the filing will delay its release even further.
https://www.newsfilecorp.com/filing/edgar/faqs.php#14
Not yet, technically.
The SEC ends its business day at 5:30pm EST.
That gives them about an hour to meet the extension deadline.
Here are some FAQ’s about Rule 12b-25.
http://www.mbbp.com/news/annual-report-deadlines
According to the source, there doesn’t seem to be any additional extensions available to filers.
We really should see something tomorrow, notwithstanding some “extraordinary circumstances.”
Anyone else think that this may have been a huge contributing factor to NASDAQ uplisting?
If Mona’s resignation was being contested (or at least not entirely finalized) it would certainly give NASDAQ justifiable reason for delaying the application.
Also, when asked about the NASDAQ application, Dowling has been almost intentionally dodgy. If Mona’s resignation was in dispute, and also a material factor to the NASDAQ uplisting, he certainly wouldn’t be able to comment on it publicly.
I wouldn’t be surprised to see more on the NASDAQ application soon.
Certainly. CANB has a very well established history of moving quickly on news, and we all know news is coming very soon.
CDEL has moved its bid up from
.038 to .04 in just the last 15 minutes, trying to get shares.
Expecting a strong close today.
Yes, this seems like a good entry point. There is a considerable amount of support around .038.
I suspect this will whip tail (or consolidate) for the next several weeks before taking off as 2019 Q1 financials near.
PR concerns ticker symbol CNAB.
This is CANB.
Simple mistake.
We were sub .03 at the end of November, ran over .10 two weeks later.
Maybe sub .03 wouldn’t be so bad..
My thoughts exactly.
Even if insiders (or “friends”) were able to dump 500 million shares at this price, they’d only make $20 million. If a dump ensues, the price drops, and they make substantially less than that.
Assuming their recent activity (TENS, SAM, Pureleaf, etc.) comes to fruition, they stand to make much more in the very near term.
What seems like the more probable scenario?
That’s correct, an increase in AS, in and of itself, doesn’t mean much.
However, the increase will likely be used to promote the “dilution scam” argument.
Nonetheless, I thought the bigger takeaway from today’s news was that CANB is no longer using Island Stock Transfer (likely due to the recent controversy), and is now using TranShare instead. To me, it seems that the company is attempting to dissociate itself from any foreseeable controversy - which is a good thing.
Increases the authorized shares (AS) to 1.5 BILLION - not million.
There are currently 535,858,000 shares issued (OS).
Increasing the AS gives the company more shares to issue (often considered dilution) for a variety of reasons, typically to finance their operations.
That’s right. Historically, CANB has reported just a few days after the deadline.
10K to be submitted late. 8K our regarding Island Stock Transfer
http://app.quotemedia.com/quotetools/showFiling.go?webmasterId=501&name=CANBIOLA,%20INC.:%208-K,%20Sub-Doc%201,%20Page%202&link=http%3A//quotemedia.10kwizard.com/filing.xml%3Frid%3D23%26ipage%3D12813454%26DSEQ%3D1%26SQDESC%3DSECTION_BODY%26doc%3D1&cp=on